Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Randomized Controlled Trial

Research Support, Non-U.S. Gov't

Clinical Trial

Comparative Study

Multicenter Study

Review

Clinical Trial, Phase I

Research Support, N.I.H., Extramural

Publication Year

From

Quick links

Individual year

2025

2019

2017

2016

2015

2014

2013

2012

2011

2010

2008

2007

2006

2004

2001

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Cytochrome P-450 CYP2D6 Inhibitors""[mesh_terms]

24 Results

Searching titles within these results

The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes.

N Chauret, B Dobbs, R L Lackman, K Bateman, D A Nicoll-Griffith, D M Stresser, J M Ackermann, S D Turner, V P Miller, C L Crespi

Drug metabolism and disposition: the biological fate of chemicals 2001;29(9):1196-200

Full Text

Abstract

Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.

P Dorado, R Berecz, E M Peñas-Lledó, M C Cáceres, A Llerena

Current drug targets 2007;7(12):1671-80

Full Text

Abstract

Crystal structure of human cytochrome P450 2D6 with prinomastat bound.

Eric F Johnson, C David Stout, Mei-Hui Hsu, Uzen Savas, An Wang

The Journal of biological chemistry 2012;287(14):10834-43

Free Full Text

Abstract

In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach.

Julia Dinger, Markus R Meyer, Hans H Maurer

Archives of toxicology 2017;90(2):305-18

Full Text

Abstract

Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans.

Bill J Gurley, Ashley Swain, Gary W Barone, D Keith Williams, Philip Breen, C Ryan Yates, Leslie B Stuart, Martha A Hubbard, Yudong Tong, Sreekhar Cheboyina

Drug metabolism and disposition: the biological fate of chemicals 2007;35(2):240-5

Free Full Text

Abstract

Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.

Paul Glue, Helen Winter, Kira Garbe, Hannah Jakobi, Alexander Lyudin, Zoe Lenagh-Glue, C Tak Hung

Journal of clinical pharmacology 2016;55(6):680-7

Full Text

Abstract

In silico study on the inhibitory interaction of drugs with wild-type CYP2D6.1 and the natural variant CYP2D6.17.

Koichi Handa, Izumi Nakagome, Noriyuki Yamaotsu, Hiroaki Gouda, Shuichi Hirono

Drug metabolism and pharmacokinetics 2014;29(1):52-60

Free Full Text

Abstract

Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.

Juha Grönlund, Teijo Saari, Nora Hagelberg, Ilkka K Martikainen, Pertti J Neuvonen, Klaus T Olkkola, Kari Laine

Journal of clinical pharmacology 2010;50(1):101-8

Full Text

Abstract

Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.

Henriette Meyer Zu Schwabedissen, Isidora Avedisian, Edna Grünblatt, Anna M Becker, Isabelle Straumann, Jan Thomann, Dino Luethi, Livio Erne, Matthias E Liechti, Lorenz Mueller, Mélusine Humbert-Droz, Alen Jelušić, Avram Tolev

Clinical pharmacology and therapeutics 2025;117(6):1784-1792

Free Full Text

Abstract

Dextromethorphan and quinidine combination for heroin detoxification.

Evaristo Akerele, Adam Bisaga, Maria A Sullivan, Fatima Garawi, Sandra D Comer, Anil A Thomas, Edward V Nunes, Herbert D Kleber

The American journal on addictions 2008;17(3):176-80

Free Full Text

Abstract

Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies.

Daisuke Nakashima, Hirotaka Takama, Yuko Ogasawara, Tetsuyoshi Kawakami, Tsuyoshi Nishitoba, Sakuo Hoshi, Eiji Uchida, Hideji Tanaka

Journal of clinical pharmacology 2007;47(10):1311-9

Full Text

Abstract

An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.

Gary L Pattee, James P Wymer, Catherine Lomen-Hoerth, Stanley H Appel, Andrea E Formella, Laura E Pope

Current medical research and opinion 2015;30(11):2255-65

Free Full Text

Abstract

Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.

Oliver Kummer, Felix Hammann, Claudine Moser, Olivier Schaller, Jürgen Drewe, Stephan Krähenbühl

European journal of clinical pharmacology 2011;67(1):63-71

Full Text

Abstract

A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions.

David F V Lewis, Maurice Dickins, Brian G Lake, Peter S Goldfarb

Drug metabolism and drug interactions 2004;19(3):189-210

Full Text

Abstract

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.

B R Brooks, R A Thisted, S H Appel, W G Bradley, R K Olney, J E Berg, L E Pope, R A Smith

Neurology 2006;63(8):1364-70

Full Text

Abstract

Results: 1 – 15 / 24

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Cytochrome P-450 CYP2D6 Inhibitors""[mesh_terms]

The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes.

Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.

Crystal structure of human cytochrome P450 2D6 with prinomastat bound.

In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach.

Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans.

Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.

In silico study on the inhibitory interaction of drugs with wild-type CYP2D6.1 and the natural variant CYP2D6.17.

Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.

Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.

Dextromethorphan and quinidine combination for heroin detoxification.

Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies.

An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.

Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.

A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions.

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.

Results for
""Cytochrome P-450 CYP2D6 Inhibitors""[mesh_terms]